Evidence map›Paper›PMID 35209053›Full record

ArticleMolecules (Basel, Switzerland)2022

Drug Design, Synthesis and Biological Evaluation of Heterocyclic Molecules as Anti-Inflammatory Agents.

Jignasa Savjani, Bhavesh Variya, Snehal Patel, Suja Mulamkattil, Harsh Amin, Shital Butani, Ahmed Allam, Jamaan Ajarem, Harsh Shah

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 5 countries.

Jignasa SavjaniDepartment of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, S.G.Highway, Ahmedabad 382481, India.
Bhavesh VariyaDepartment of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, S.G.Highway, Ahmedabad 382481, India.
Snehal PatelDepartment of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, S.G.Highway, Ahmedabad 382481, India.
Suja MulamkattilDepartment of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, S.G.Highway, Ahmedabad 382481, India.
Harsh AminDepartment of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, S.G.Highway, Ahmedabad 382481, India.ORCID 0000-0002-0272-5465
Shital ButaniDepartment of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, S.G.Highway, Ahmedabad 382481, India.
Ahmed AllamZoology Department, Faculty of Science, Beni-Suef University, Beni-Suef 65211, Egypt.
Jamaan AjaremZoology Department, College of Science, King Saud University, Riyadh 11451, Saudi Arabia.
Harsh ShahJ-Star Research Inc., 6 Cedar Brook Drive, Cranbury, NJ 08512, USA.
Nirma University · INBeni-Suef University · EGKing Saud University · SAStar Technology and Research (United States) · USUniversity of Alberta · CA

Funding

King Saud University RSP-2021/149
6 · The paper itself

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are generally utilized for numerous inflammatory ailments. The long-term utilization of NSAIDs prompts adverse reactions such as gastrointestinal ulceration, renal dysfunction and hepatotoxicity; however, selective COX-2 inhibitors prevent these adverse events. Various scientific approaches have been employed to identify safer COX-2 inhibitors, as in any case, a large portion of particular COX-2 inhibitors have been retracted from the market because of severe cardiovascular events. This study aimed to develop and synthesize a novel series of indomethacin analogues with potential anti-inflammatory properties and fewer side effects, wherein carboxylic acid moiety was substituted using DCC/DMAP coupling. This study incorporates the docking of various indomethacin analogues to detect the binding interactions with COX-2 protein (PDB ID: 3NT1). MD simulation was performed to measure the stability and flexibility of ligand-protein interactions at the atomic level, for which the top-scoring ligand-protein complex was selected. These compounds were evaluated in vitro for COX enzymes inhibition. Likewise, selected compounds were screened in vivo for anti-inflammatory potential using the carrageenan-induced rat paw oedema method and their ulcerogenic potential. The acute toxicity of compounds was also predicted using in silico tools. Most of the compounds exhibited the potent inhibition of both COX enzymes; however,

Indexed as

Chemistry Techniques, SyntheticDrug DesignAnti-Inflammatory Agents, Non-SteroidalBiomarkersCyclooxygenase 2 InhibitorsDose-Response Relationship, DrugHeterocyclic CompoundsIndomethacinLigandsMolecular Docking SimulationMolecular Dynamics SimulationMolecular StructureProteinsStructure-Activity RelationshipAnti-Inflammatory Agents, Non-SteroidalBiomarkersCyclooxygenase 2 InhibitorsHeterocyclic CompoundsIndomethacinLigandsProteinsanti-inflammatory agentsCOX-2 inhibitorsgastrointestinal safety studyindomethacinmolecular modelling

Identifiers

PMID35209053
PMCPMC8876616
OpenAlexW4213100248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.